Oral MS drug Gilenya has yet to show ‘full potential'
Oral MS drug Gilenya has yet to show ‘full potential'
Novartis's multiple sclerosis pill Gilenya, which faces a threat from a rival product under development by Biogen Idec Inc, has yet to show its full potential, the Swiss drugmaker’s head of development said.
Gilenya, approved by U.S. regulators last year as the first pill against relapsing forms of multiple sclerosis, may also work in patients with a more severe form of the disease called primary progressive, Novartis’s Trevor Mundel said yesterday in a telephone interview. “We haven’t seen the full potential with Gilenya,” according to Mundel.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 170 Views
-
Last post by DIM
-
- 0 Replies
- 2778 Views
-
Last post by NHE
-
- 1 Replies
- 1147 Views
-
Last post by Petr75
-
- 0 Replies
- 171 Views
-
Last post by NHE
-
- 5 Replies
- 14898 Views
-
Last post by gibbledygook
-
- 0 Replies
- 560 Views
-
Last post by NHE
-
- 0 Replies
- 1683 Views
-
Last post by NHE
-
- 1 Replies
- 3185 Views
-
Last post by Tif
-
- 2 Replies
- 1114 Views
-
Last post by DIM